Antitumor activity of a 5T4 targeting antibody drug conjugate with a novel payload derived from MMAF via C‐Lock linker
Open Access
- 7 March 2019
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 8 (4) , 1793-1805
Abstract
Antibody‐drug conjugates (ADCs) belong to a promising class of biopharmaceuticals in which target‐killing of tumor cells was achieved by marrying the potency of the cytotoxic payload with the tumor specificity of the antibody. Here we developed a novel ADC (ZV0508) that targets 5T4 oncofetal antigen, which is overexpressed in many carcinomas on both bulk tumor cells and cancer stem cells. A novel cytotoxic payload called Duostatin‐5 (Duo‐5) which was derived from monomethyl auristatin F (MMAF) was attached to a 5T4 targeting antibody (ZV05) by interchain cysteine cross‐linking conjugation via a disubstituted C‐Lock linker. We have investigated the antitumor efficacy of ZV0508 by in vitro and in vivo studies, and compared its antitumor activity with ZV05‐mcMMAF (ZV0501), in which MMAF was linked via a conventional noncleavable maleimidocaproyl linker. As results, ZV0508 exhibited ideal antiproliferative effects through blocking cell cycle and inducing cell apoptosis. The in vivo studies revealed that both ZV0501 and ZV0508 exhibited excellent antitumor activities even at a single dose. Although ZV0508 was inferior to ZV0501 in vitro, it elicited more durable antitumor responses than ZV0501 in vivo. The superior in vivo activity of ZV0508 may be due to the combined use of the disubstituted C‐Lock linker and the novel payload Duo‐5, resulting in a more stable and potent ADC. Taken together, these data suggest ZV0508 is a worthy candidate for the treatment of 5T4 positive cancers.Keywords
Funding Information
- Research and Development (2017YFC0908600, 81430081)
This publication has 40 references indexed in Scilit:
- Vaccination of castration-resistant prostate cancer patients with TroVax (MVA–5T4) in combination with docetaxel: a randomized phase II trialCancer Immunology, Immunotherapy, 2013
- Long-term Tumor Regression Induced by an Antibody–Drug Conjugate That Targets 5T4, an Oncofetal Antigen Expressed on Tumor-Initiating CellsMolecular Cancer Therapeutics, 2013
- Delineation of a Cellular Hierarchy in Lung Cancer Reveals an Oncofetal Antigen Expressed on Tumor-Initiating CellsCancer Research, 2011
- Gemtuzumab ozogamicin in the treatment of acute myeloid leukemiaCancer Treatment Reviews, 2008
- Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery: Effects of Linker Technology on Efficacy and ToxicityBioconjugate Chemistry, 2005
- Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug ConjugateClinical Cancer Research, 2004
- Glycosylation and epitope mapping of the 5T4 glycoprotein oncofoetal antigenBiochemical Journal, 2002
- 5T4 oncofetal antigen expression in ovarian carcinomaInternational Journal of Gynecological Cancer, 1995
- Trophoblast glycoprotein recognised by monoclonal antibody 5T4 maps to human chromosome 6q14?q15Human Genetics, 1990
- Isolation and characterization of 5T4, a tumour‐associated antigenInternational Journal of Cancer, 1990